| Date | Title | Description |
| 13.11.2024 | Andera Partners continues its international expansion and announces the opening of a Madrid office | Gonzalo Boada joins Andera Partners as a Director within the Andera MidCap team, which invests in medium-sized companies (with revenue between €50 and €500 million) to accelerate their change of scale and their internationalization. The mai... |
| 24.11.2021 | (English) Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M | Caixa Capital Risc, the venture capital subsidiary of CriteriaCaixa, today announces the sale of its portfolio company Sanifit Therapeutics to Vifor Pharma, a global pharmaceutical company that aims to become an industry leader in iron defi... |
| 22.11.2021 | Vifor Pharma adquirirá Sanifit para reforzar su cartera de productos en fase avanzada en nefrología |
St. Gallen, Suiza, y Palma, España, 19 de noviembre de 2021 – Vifor Pharma y Sanifit Therapeutics, compañía biofarmacéutica cardio-renal en fase clínica centrada en tratamientos para trastornos de calcificación vascular progresiva, han ... |
| 22.11.2021 | Vifor Pharma adquirirá Sanifit, participada por Ysios Capital, CaixaCR, AltaLS, ColumbusVP, Healthequity y el CDTI | 22/11/2021
Nota de prensa
VIFOR PHARMA ADQUIRIRÁ SANIFIT PARA REFORZAR SU CARTERA DE PRODUCTOS EN FASE AVANZADA EN NEFROLOGÍA.
• Vifor Pharma adquirirá Sanifit, una compañía biofarmacéutica cardio-renal en fase clínica centrada en tratam... |
| 22.11.2021 | Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology |
St. Gallen, Switzerland, and Palma, Spain, 19 November 2021 – Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today ann... |
| 11.02.2021 | Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease | https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/ |
| 01.06.2020 | Sanifit Enhances Leadership Team with New Executive Appointments | Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience
Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focus... |
| 31.10.2019 | Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis. | Top line data to be presented at 2019 Scientific Sessions of American Heart Association
Webcast to be held on Monday 18 November at 11.00 ET
Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical co... |
| 30.10.2019 | Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech | → Rare disease biotech Sanifit — which in June, raised nearly $81 million in Spain’s largest-ever private biotech fundraise — has announced that its international Phase IIb CaLIPSO study of SNF472 met its primary endpoint. Th... |
| 30.10.2019 | Sanifit, owned by Ysios Capital, announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint | 30/10/2019
Nota de prensa
SANIFIT, OWNED BY YSIOS CAPITAL, ANNOUNCES THAT THE PHASE 2B CALIPSO TRIAL OF SNF472 MET ITS PRIMARY ENDPOINT.
• Venture capital firm Ysios Capital led the 36,6M€ Series C round in 2015 creating a relevant inter... |
| 28.06.2019 | Spain and San Diego Based Sanifit Raises $80.9 Million | Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising.
The financing consis... |
| 28.06.2019 | Term Sheet — Friday June 28 | APPLE’S AUTONOMOUS VEHICLE AMBITIONS
Hello Term Sheet readers. Lucinda here again until Polina’s return following the July 4 holidays. In the meantime, please send deals to lucinda.shen@fortune.com.
Paid Content You can't secure what you ca... |
| 28.06.2019 | Alta Life Sciences participates in Sanifit’s 55,2M€ Series D round led by Caixa Capital Risc | Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million)... |
| 28.06.2019 | Spain and San Diego Based Sanifit Raises $80.9 Million | Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising.
The financing consis... |
| 26.06.2019 | Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise | Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private... |
| 26.06.2019 | Sanifit Raises €72.2M in Financing | Sanifit, a Palma, Spain and San Diego, USA-based clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, closed a €72.2m ($80.9m) funding round.
The financing consists of:
– a €55.2m ... |
| 26.06.2019 | Caixa Capital Risc lidera la mayor ronda de biotecnología en España, con €55M en Sanifit. Participan Columbus, Alta Life y anteriores inversores. | 26/06/2019
Nota de prensa
CAIXA CAPITAL RISC LIDERA LA MAYOR RONDA DE BIOTECNOLOGÍA EN ESPAÑA, CON €55M. EN SANIFIT. PARTICIPAN COLUMBUS, ALTA LIFE Y ANTERIORES INVERSORES.
La entidad de capital riesgo (venture capital) Caixa Capital Ris... |
| 25.10.2016 | Spanish biotech sector gets a boost with $140 million VC fund | “With our recent investments we have been able to attract specialized international funds and corporate venture funds to Spain, which represents an inflection point for the country´s biotech sector,” said Joel Jean-Mairet, partner at Ysios ... |
| 07.06.2016 | Sanifit, participada por Ysios, incorpora a Preston S. Klassen como director médico y abre sede en EEUU | 07/06/2016
SANIFIT, PARTICIPADA POR YSIOS CAPITAL, INCORPORA A PRESTON S. KLASSEN COMO NUEVO DIRECTOR MÉDICO Y ABRE SEDE EN EEUU.
Sanifit, compañía participada por la entidad de capital riesgo (venture capital) Ysios Capital, ha incorpora... |
| 08.09.2015 | Sanifit raises €36.6M ($41.3M) in Series C financing round | Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M ($41.3M) in a Series C financing round. The company is focused on the development of SNF472, an experimental drug for the treatm... |
| 08.09.2015 | Sanifit cierra una ronda de €36,6M liderada por Ysios. Acuden Caixa CR, Lundbeck fonden, Forbion, Gilde, Edmond Rothschild y Baxter | 08/09/2015
SANIFIT CIERRA UNA RONDA DE €36,6 MILLONES LIDERADA POR YSIOS. ACUDEN CAIXA CAPITAL RISC, Y LOS INTERNACIONALES LUNDBECK FONDEN, FORBION, GILDE, EDMON DE ROTHSCHILD Y BAXTER.
La empresa biofarmacéutica Laboratoris Sanifit S.L.,... |
| 08.09.2015 | Laboratoris Sanifit Raises €36.6M in Series C Financing | Laboratoris Sanifit S.L., a Palma de Mallorca, Spain-based clinical-stage biopharmaceutical company, raised €36.6M (approx. $41M) in Series C financing.
The round was led by Ysios Capital with participation from new investors Lundbeckfond V... |
| 17.11.2014 | Caixa Capital Risc lidera una ronda de €3,6 millones en Sanifit | 17/11/2014
CAIXA CAPITAL RISC LIDERA UNA RONDA DE €3,6 MILLONES EN SANIFIT.
La entidad de capital riesgo (venture capital) Caixa Capital Risc, ha liderado una ronda de financiación de €3,6 millones en la empresa Laboratorios Sanifit, ubic... |
| - | Spanish biotech sector gets a boost with $140 million VC fund | Ysios Capital Directors Josep Ll. Sanfeliu (top left), Joël Jean-Mairet, Karen Wagner, Julia Salaverria (left to right), and Cristina Garmendia (right bottom).
Institutional and private investors have given the Spanish biotech sector a powe... |
